

DiagnosTear




Transforming
Eye Disease
Management

A BioLight Company



BIOLIGHT
Life Sciences Ltd.



Leading the diagnostics of front-of-the eye diseases by offering true multiparameter analysis of the tear fluid

**An ideal drug
companion
diagnostic**

**Enables
personalized
disease treatment**



Dry Eye First:

A Multifactorial Disease

Difficult to diagnose and treat



48%

of Americans
(approximately 340 million people)
regularly experience dry eye
symptoms

1 in 3


visits to ophthalmic clinics in
the US is related
to dry eye symptoms

~ 70

companies are in
development of
new dry eye treatments


Existing Diagnostic Tools: Nonspecific & Conflicting

Current
diagnostics
measure only a
single parameter
from this
multifactorial
syndrome




The Solution to a Multifactorial Diagnosis:

Multiparameter
analysis of tear fluid:
Several tear
components
analyzed and with
algorithm combined
into one result in
minutes



Could be used as a Companion Diagnostic

Specifically tailored to identify responder's population
for a specific treatment



- Numerous new DES treatments in development. Many failures in the past



- Each patient is tested before and after treatment
- Uses a battery of different parameters



- Better patient selection
- Improved chances to study success
- Reimbursable
- Commercial differentiation

How it works

Collector

- Microfluidic device
- Collects 1 μ L of tear fluid
- Dilutes 1:200
- Dispense single drops into the cassettes

Blister (part of the collector)

- Unique liquid composition
- Comprised of aluminum
- Completely sealed

Cassette

- Multichannel
- Fluent flow of the liquid




Watch
Movie



Milestones

Major study to commence in India Q3/2021



- **Top International Manufacturer**
- **Elcam invest ~ \$3M USD**
- **Investment at ~ \$18.5M USD post money valuation**



Management



Yaacov Michlin
Chairman

CEO at BioLight (TASE: BOLT)
Former CEO BrainsWay
(NASDAQ, TASE: BWAY)
Co-Chairman at IATI
(Israel Advanced Technology Industries)




Dr. Amos Sommer, PhD
CEO

An experienced lateral flow expert
Led R&D in Alere Inc.
(Organics)

Future

AI-driven system for Various Front of the eye Diseases





Thank You!